Latest News | DRL, Aurigene Partner with DNDi to Develop Affordable, Life-saving New Drugs for NTD

Hyderabad, Aug 30 (PTI) Dr Reddy's Laboratories Ltd and its step-down subsidiary Aurigene Pharmaceutical Services Limited, on Tuesday announced a MoU with the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development organisation that develops new therapeutic solutions for neglected diseases and the DNDi India Foundation.

Also Read | Asus ROG Phone 6D Ultimate Launching on September 19, 2022.

Aurigene Pharmaceutical Services is a contract research, development and manufacturing services organisation.

Also Read | Android 14 Beta Likely To Be Launched in April 2023.

A press release from Dr Reddy's said the parties will explore a potential collaboration to develop and market novel and improved drugs for the treatment of identified Neglected Tropical Diseases (NTDs) of national and global importance.

The parties will also seek to work towards ensuring access of those drugs at affordable prices to patients in need particularly in Low and Middle-Income Countries (LMICs) that are disproportionately affected by these NTDs, it further said.

"We will look to leverage the strengths and capabilities of all the parties to explore new drugs with the intention of making them available in India and in countries with high disease burden in these NTDs," Deepak Sapra, CEO – API and Services, Dr Reddy's said.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)